Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies

Stopped The trial was suspended due to the inability to enroll qualified participants

Conditions

• Peripheral T Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Anaplastic Lymphoma
• Acute T Cell Leukemia
• T-lymphoblastic Lymphoma

Interventions

• DRUG: anti-TRBC1 CAR-T cell therapy

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine